Lanreotid Zentiva (Lanreotide)

Lanreotide mimics natural somatostatin and binds preferentially to somatostatin receptor subtypes sst2 and sst5 on endocrine and neuroendocrine cells. Receptor activation inhibits adenylate cyclase, reduces cyclic AMP and calcium influx, and consequently suppresses the secretion of growth hormone, insulin, glucagon and other peptide hormones, leading to clinical benefit in the targeted disorders.

The specific dose and dosing interval of Lanreotid Zentiva are determined by the prescribing physician based on the patient’s condition, disease severity, and response to therapy. Lanreotide is typically administered as a subcutaneous injection at intervals ranging from four weeks to longer, but exact regimens must be individualized and follow the approved product labeling.

The safety of lanreotide during pregnancy and lactation has not been fully established. Animal studies have shown adverse effects on fetal development, and there are limited human data. Consequently, lanreotide should be used only if the potential benefit justifies the potential risk to the fetus or infant, and breastfeeding mothers should discuss alternatives with their healthcare provider.

To place an order, visit the product page on gnhindia.com, enter the required quantity and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides a quotation, availability details, shipping options—including cold‑chain logistics where required—and assistance with import documentation.

The primary alternative to lanreotide is octreotide, another somatostatin analogue. Both agents bind to sst2 receptors and suppress hormone secretion, but lanreotide has a longer half‑life, allowing dosing every four weeks, whereas octreotide often requires more frequent administration. Clinical efficacy is comparable for acromegaly and neuroendocrine tumor control, while individual tolerability and injection‑site reactions may differ.

Lanreotid Zentiva must be stored in a refrigerator at 2‑8 °C (36‑46 °F). The product should be kept in its original packaging to protect it from light, should not be frozen, and must not be shaken. If temporary storage at room temperature is unavoidable, limit exposure to less than 24 hours and return the product to refrigerated conditions promptly.

Lanreotid Zentiva is supplied as an injectable solution for subcutaneous injection. A healthcare professional prepares the dose using aseptic technique, selects an appropriate injection site (typically the abdomen or thigh), and administers the medication into the subcutaneous tissue. Patients may be taught self‑injection after proper training, and the injection interval is usually every four weeks, as prescribed.

The most serious adverse events associated with lanreotide include pancreatitis, severe allergic reactions such as anaphylaxis, and cardiac conduction disturbances like bradycardia or heart block. Patients should be instructed to seek immediate medical attention if they experience intense abdominal pain, signs of an allergic reaction (e.g., swelling, difficulty breathing), or unexplained faintness, palpitations, or syncope.

Lanreotide is contraindicated in patients with known hypersensitivity to lanreotide or any of the excipients in the formulation. Caution is advised in individuals with severe hepatic impairment, uncontrolled diabetes, or active gallbladder disease, as the drug may exacerbate these conditions. Pregnant or breastfeeding women should only use it when the potential benefit outweighs the risk, and it should be avoided in patients with a history of severe pancreatitis.